Loading...
XNASKTRA
Market cap11mUSD
Oct 17, Last price  
0.22USD
Name

Kintara Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:KTRA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.05%
Shrs. gr., 5y
119.69%
Rev. gr., 5y
%
Revenues
0k
Net income
-9m
L-41.97%
-5,582-33,136-18,88508,290,689,000,000-4,796,030-8,864,864-8,081,764-11,138,312-7,408,375-10,107,288-38,324,000-22,619,000-14,649,000-8,501,000
CFO
-7m
L-39.52%
-4,930-38,788-11,385-5,520,499-3,853,069-5,145,814-8,019,071-9,850,850-6,327,425-7,927,516-18,860,000-20,392,000-11,865,000-7,176,000
Earnings
Feb 12, 2025

Profile

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
URL
https://www.kintara.com/
IPO date
Jul 12, 2016
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
Cost of revenue
8,506
14,856
22,742
Unusual Expense (Income)
NOPBT
(8,506)
(14,856)
(22,742)
NOPBT Margin
Operating Taxes
76
(147)
(42)
Tax Rate
NOPAT
(8,582)
(14,709)
(22,700)
Net income
(8,501)
-41.97%
(14,649)
-35.24%
(22,619)
-40.98%
Dividends
(6)
(8)
(8)
Dividend yield
0.84%
0.12%
2.95%
Proceeds from repurchase of equity
10,576
1,903
21,569
BB yield
-1,485.88%
-27.79%
-7,965.74%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
186
166
163
Net debt
(4,909)
(1,535)
(11,783)
Cash flow
Cash from operating activities
(7,176)
(11,865)
(20,392)
CAPEX
(20)
(232)
Cash from investing activities
(20)
(232)
964
Cash from financing activities
10,570
1,852
21,635
FCF
(8,604)
(15,271)
(22,640)
Balance
Cash
4,909
1,535
11,780
Long term investments
3
Excess cash
4,909
1,535
11,783
Stockholders' equity
(149,548)
(140,707)
(123,715)
Invested Capital
153,491
141,604
135,673
ROIC
ROCE
EV
Common stock shares outstanding
2,635
1,700
974
Price
0.27
-93.30%
4.03
1,349.64%
0.28
-87.75%
Market cap
712
-89.61%
6,849
2,429.43%
271
-76.96%
EV
6,055
15,959
1,042
EBITDA
(8,451)
(14,796)
(22,682)
EV/EBITDA
Interest
14
Interest/NOPBT